Our group demonstrated that daily administration of the CGRP analog [50 nmol/kg/day, subcutaneous injection (s.c.)] for 2 weeks in AngII-treated mice led to significant attenuation of AngII-induced hypertension and protected against vascular, renal and cardiac dysfunction. Here, CALCA is linked to hypertensive disorder.